Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Extranodal NK-T-Cell × pegaspargase × 30 days × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Burkitt Lymphoma 7 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Lymphoma, Extranodal NK-T-Cell 1 Leukemia, Biphenotypic, Acute 1 Leukemia 1 Down Syndrome 1

Interventions

relatlimab 1 pegaspargase 1 Vorinostat 1 Nivolumab 1 Azacitidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07457177 2026-03-09

Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL

Beijing Tongren Hospital

Phase 2 Not yet recruiting

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡